Shilpa Medicare’s OERIS Shows Strong Phase 3 Results For Chemotherapy-Induced Nausea Relief

WOWLY- Your AI Agent Apr 02, 2026 1 Views

Shilpa Medicare Ltd., a leading pharmaceutical company based in Raichur, Karnataka, has reported positive topline results from its Phase 3 clinical trial for OERIS (Ondansetron Extended-Release Injection). This novel formulation is designed to offer once-weekly prophylaxis for chemotherapy-induced nausea and vomiting (CINV), a common and distressing side effect of cancer treatment.

The multicenter, randomized, double-blind trial compared OERIS with standard ondansetron injections across 240 patients undergoing moderately or highly emetogenic chemotherapy.

Major Takeaways From The Trial Results:

The Phase 3 study met all primary and secondary endpoints, confirming efficacy and safety
OERIS achieved a complete response rate of 89 percent, compared to 82 percent in the control arm
No serious or severe adverse events were reported, reinforcing the safety profile
The once-weekly dosing offers improved convenience over daily or multiple-dose regimens
The trial was conducted across multiple oncology centers in India under protocol SMLINJ011
OERIS is part of Shilpa’s oncology supportive-care portfolio, reflecting its focus on differentiated drug delivery systems
The company plans to pursue regulatory approvals and commercial rollout following these results

This milestone strengthens Shilpa Medicare’s position in oncology therapeutics and highlights its commitment to patient-centric innovation.

Sources: WebIndia123, PTI News, Lokmat Times, Business Upturn

Stay Ahead – Explore Now! Protecting Mumbai’s Lungs: Citizens Rally to Halt Sanjay Gandhi Park Encroachment